Showing 4741-4750 of 7247 results for "".
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasishttps://practicaldermatology.com/news/envudeucitinib-enables-durable-treat-to-target-control-in-plaque-psoriasis/2485542/Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasi
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- Arcutis Ends Kowa Promotional Partnership, Assumes Control of ZORYVE Promotionshttps://practicaldermatology.com/news/arcutis-ends-kowa-deal-assumes-full-control-of-zoryve-outreach/2485454/Arcutis Biotherapeutics has terminated its co-promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE® (roflumilast), effective January 23, 2026, according to a press relase from the company. Under the prior arran
- Rapid Regrowth Tops Treatment Goals for Alopecia Areata: Surveyhttps://practicaldermatology.com/news/rapid-regrowth-tops-treatment-goals-for-alopecia-areata-survey-finds/2485419/Results from a new national survey presented at the 2026 Winter Clinical Dermatology Hawaii reveals that most US clinicians prioritize rapid and nearly complete hair regrowth, with strong satisfaction reported for Janus kinase (JAK) inhibitor therapies.
- Low-Dose Minocycline Superior in Treating Inflammatory Rosaceahttps://practicaldermatology.com/news/low-dose-minocycline-dfd-29-superior-in-treating-inflammatory-rosacea/2485398/New data presented at 2026 Winter Clinical Hawaii showed DFD-29, a modified low-dose oral minocycline 40 mg, significantly outperformed both placebo and doxycycline 40 mg in the treatment of inflammatory lesions in patients with moderate-to-severe rosacea.
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- Study: Upadacitinib Reduces Inflammation Markers in ADhttps://practicaldermatology.com/news/study-upadacitinib-reduces-inflammation-markers-in-ad/2485380/Upadacitinib (UPA) treatment was associated with significant reductions in biomarkers of systemic inflammation in adults with moderate-to-severe atopic dermatitis (AD), according to a poster presented at Winter Clinical 2026 in Hawaii.
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d